Debra Richardson to Angiogenesis Inhibitors
This is a "connection" page, showing publications Debra Richardson has written about Angiogenesis Inhibitors.
Connection Strength
0.271
-
Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. Curr Oncol Rep. 2019 02 26; 21(3):22.
Score: 0.151
-
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 04; 161(1):113-121.
Score: 0.043
-
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer. 2020 05; 30(5):596-601.
Score: 0.040
-
Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer. Am J Clin Oncol. 2018 10; 41(10):933-937.
Score: 0.037